Home › Metastatic Cancer › Wisconsin › Madison
Metastatic Cancer clinical trials in Madison, WI
21 studies for Metastatic Cancer are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center, Madison
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
RecruitingPhase 1
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RecruitingPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
- Wisconsin Institute for Medical Research, Madison
A Study of ASP3082 in Adults With Advanced Solid Tumors
RecruitingPhase 1
- University of Wisconsin Hospital, Madison
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical, Madison
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Biomarkers to Detect Endocrine Therapy Resistance
RecruitingPhase 2
- UW Carbone Cancer Center, Madison
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RecruitingPhase 1
- UW Carbone Cancer Center, Madison
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- University of Wisconsin, Carbone Cancer Center, Madison
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
RecruitingPhase 1
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
RecruitingPhase 1
- University of Wisconsin, Madison
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RecruitingPhase 2/3
- William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- University Of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- UW Carbone Cancer Center, Madison
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
RecruitingPhase 1
- University of Wisconsin Carbone Cancer Center, Madison
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
RecruitingPhase 1
- SSM Health Cancer Care, Madison
In Vivo Liquid Biopsy of Melanoma (Cytophone)
RecruitingHealthy volunteers welcome
- SSM Health Dean Medical Group Specialty Services, Madison
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer23 studies
- Breast Cancer22 studies
- Acute Myeloid Leukemia16 studies
- Non-Small Cell Lung Cancer16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Pancreatic Cancer10 studies
- Lung Cancer10 studies
- Multiple Myeloma9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.